We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The National Institutes of Health is sponsoring a clinical trial of Gilead Sciences’ antiviral remdesivir combined with Eli Lilly’s anti-inflammatory Olumiant (baricitinib) for treatment of COVID-19 infections. Read More
HHS has not yet used its new authority under the 21st Century Cures Act to recruit more senior biomedical scientists for the FDA and other agencies, the Government Accountability Office said in a new report released Friday. Read More
Maryland Gov. Larry Hogan last week vetoed legislation that would have funded the state’s Prescription Drug Affordability Board, an independent body established last year to evaluate costly drugs and set price caps. Read More
Following widespread criticism of the federal government’s handling of COVID-19 treatment remdesivir, HHS released details on Saturday of its distribution plan of the drug, and said states will make the final call on which hospitals get the drug. Read More
Three of the nation’s top medical experts heading up the nation’s response to COVID-19 are now in quarantine after being exposed to the coronavirus. Read More
California biotech firm Sorrento Therapeutics and New York City’s Mount Sinai Health System are teaming up to test and develop a triple antibody cocktail that could potentially treat or help prevent COVID-19. Read More
About 28 million doses of hydroxychloroquine were distributed from the Strategic National Stockpile last month and states are wondering what to do with their excess supply since studies have cast doubt on the drug’s benefit as a COVID-19 treatment. Read More
The Office of Special Counsel (OSC) has recommended that Rick Bright be temporarily reinstated to his position as director of HHS’ Biomedical Advanced Research and Development Authority. Read More